Human Metabolome Technologies, Inc. 6090
γƒ’γƒ₯γƒΌγƒžγƒ³γƒ»γƒ‘γ‚Ώγƒœγƒ­γƒΌγƒ γƒ»γƒ†γ‚―γƒŽγƒ­γ‚ΈγƒΌγ‚Ίζ ͺ式会瀾 Β· Services Β· Standard
Governance Compliance: TSE Status: Disclosed
Similar β€Ί
Fact Sheet (PDF)
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. Human Metabolome Technologies, Inc. has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Price
Β₯610
Market Cap
Β₯3.5B
Ent. Value
Β₯2.0B
Net Cash
Β₯1.5B
Shares Out.
5.7M
P / E
14.0Γ—
EV / EBIT
8.1Γ—
P / Book
1.84Γ—
P / NCAV
2.48Γ—
Div. Yield
2.46%
⬇ Excel
Metric FY 2026
TDnet 		FY 2025
EDINET β†— 		FY 2024
EDINET β†— 		FY 2023
EDINET β†— 		FY 2022
EDINET β†— 		FY 2021
EDINET β†—
Net Sales Β₯1.6B Β₯1.5B Β₯1.3B Β₯1.3B Β₯1.2B Β₯1.1B
Cost of Sales β€” Β₯533M Β₯476M Β₯439M Β₯383M Β₯318M
Gross Profit β€” Β₯922M Β₯869M Β₯860M Β₯840M Β₯806M
SG&A β€” Β₯672M Β₯649M Β₯649M Β₯649M Β₯767M
Operating Income β€” Β₯250M Β₯220M Β₯211M Β₯191M Β₯39M
Non-Operating Income β€” Β₯5M Β₯23M Β₯24M Β₯64M Β₯22M
Non-Operating Expenses β€” Β₯13M Β₯2M Β₯2M Β₯3M Β₯2M
Interest Expense β€” Β₯2M Β₯2M Β₯2M Β₯2M Β₯2M
Ordinary Income Β₯1.6B Β₯241M Β₯241M Β₯233M Β₯253M Β₯60M
Pre-tax Income β€” Β₯270M Β₯262M Β₯237M Β₯262M Β₯51M
Income Taxes β€” Β₯13M Β₯19M Β₯-49M Β₯-6M Β₯-7M
Current Tax β€” Β₯24M Β₯29M Β₯22M Β₯31M Β₯21M
Deferred Tax β€” Β₯-11M Β₯-10M Β₯-71M Β₯-37M Β₯-29M
Net Income (owners) Β₯1M Β₯256M Β₯243M Β₯286M Β₯268M Β₯58M
Comprehensive Income β€” Β₯250M Β₯248M Β₯284M Β₯234M Β₯53M
EBITDA β€” Β₯353M Β₯306M Β₯291M Β₯256M Β₯95M
EPS β€” Β₯43.67 Β₯41.14 Β₯48.39 Β₯45.39 Β₯9.87
Shares Outstanding β€” 5.7M 5.9M 5.9M 5.9M 5.9M
Shares Issued (total) β€” 5.9M 5.9M 5.9M 5.9M 5.9M
Treasury Shares β€” 0.2M 0.0M 0.0M 0.0M 0.0M